Latest news with #Viatris
Malaysian Reserve
15 hours ago
- Business
- Malaysian Reserve
Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit
NEW YORK, June 1, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the 'Class Period'), of the important June 3, 2025 lead plaintiff deadline. So what: If you purchased Viatris securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Viatris class action, go to call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Defendants' statements, albeit made months after the initial inspection and defendants' initiation of remediation efforts included, among other things, the disclosure of the FDA's issuance of a warning letter and import alert which would prevent Viatris from shipping eleven products from the Indore facility, though four of such were exempt from the limitations (the 'Warning Letter'). Defendants routinely referred to the impact of the Warning Letter as a mere 'minor headwind' for Viatris. Further, defendants provided these disclosures to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state impact of the Warning Letter on Viatris' financials. Notably, defendants did not disclose precisely when the inspection occurred, how long the remediation efforts had been implemented, or the financial impact of the existing and continued remediation efforts. Defendants further notably failed to disclose which products were subject to the FDA Warning Letter, which products were subject to exemptions, and the significance of the restricted products with respect to Viatris' existing financials and future projections, and for which Viatris believed it would obtain exemptions. Such statements, absent these material facts, caused Plaintiff and other shareholders to purchase Viatris' securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Viatris class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
Associated Press
16 hours ago
- Business
- Associated Press
Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit
NEW YORK, June 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the 'Class Period'), of the important June 3, 2025 lead plaintiff deadline. So what: If you purchased Viatris securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Viatris class action, go to call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Defendants' statements, albeit made months after the initial inspection and defendants' initiation of remediation efforts included, among other things, the disclosure of the FDA's issuance of a warning letter and import alert which would prevent Viatris from shipping eleven products from the Indore facility, though four of such were exempt from the limitations (the 'Warning Letter'). Defendants routinely referred to the impact of the Warning Letter as a mere 'minor headwind' for Viatris. Further, defendants provided these disclosures to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state impact of the Warning Letter on Viatris' financials. Notably, defendants did not disclose precisely when the inspection occurred, how long the remediation efforts had been implemented, or the financial impact of the existing and continued remediation efforts. Defendants further notably failed to disclose which products were subject to the FDA Warning Letter, which products were subject to exemptions, and the significance of the restricted products with respect to Viatris' existing financials and future projections, and for which Viatris believed it would obtain exemptions. Such statements, absent these material facts, caused Plaintiff and other shareholders to purchase Viatris' securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Viatris class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] View original content to download multimedia: SOURCE THE ROSEN LAW FIRM, P. A.
Associated Press
2 days ago
- Business
- Associated Press
VIATRIS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--May 30, 2025-- Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. ('Viatris' or 'the Company') (NasdaqGS: VTRS), if they purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the 'Class Period'). This action is pending in the United States District Court for the Western District of Pennsylvania. What You May Do If you purchased securities of Viatris and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by June 3, 2025. About the Lawsuit Viatris and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On February 27, 2025, the Company announced its financial results for the fourth quarter and full fiscal year 2024, disclosing disappointing fiscal 2025 guidance, which the Company attributed to 'the expected financial impact from Indore facility warning letter and import alert.' On this news, the price of Viatris' shares fell from $11.24 per share on February 26, 2025. Viatris' stock price fell to $9.53 per share on February 27, 2025. The case is Quinn v. Viatris Inc., et al., No. 25-cv-466. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit CONNECT WITH US: FaceBook || Instagram || YouTube || TikTok || LinkedIn View source version on CONTACT: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 KEYWORD: LOUISIANA NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Kahn Swick & Foti, LLC Copyright Business Wire 2025. PUB: 05/30/2025 05:26 PM/DISC: 05/30/2025 05:25 PM
Business Wire
3 days ago
- Business
- Business Wire
Deadline Soon: Viatris Inc. (VTRS) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming June 3, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Viatris Inc. ('Viatris' or the 'Company') (NASDAQ: VTRS) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON VIATRIS INC. (VTRS), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On December 23, 2024, Viatris disclosed that 'following an inspection by the U.S. FDA' at the Company's manufacturing facility in Indore 'the Agency has issued a Warning Letter, and an Import Alert related to this facility' which 'affects 11 actively distributed products that will no longer be accepted into the U.S. until the Warning Letter is lifted.' Then, on February 27, 2025, Viatris released its fourth quarter and full year 2024 financial results, reporting, among other things, financial guidance metrics for fiscal year 2025 with 'anticipated negative impact from the Indore facility of ~$500 million to total revenues and ~$385 million to adjusted EBITDA.' On this news, Viatris' stock price fell $1.71, or 15.2%, to close at $9.53 per share on February 27, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Viatris' efforts to downplay the ramifications of the Indore facility's failed FDA inspection fell short of reality; (2) the impact to the Company's projected fiscal year 2025 finances from the combination of the ongoing remediation efforts at the facility, the inability for the facility to manufacture and ship key products for the Company, particularly Lenalidomide, the inability for Viatris to convince the FDA to expand the exempt list to include such drugs, and an associated impact on shipments to other regions from the Indore facility was significant and resulted in much more than 'a little bit' of a headwind; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Viatris securities between August 8, 2024, to February 26, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is June 3, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Upturn
3 days ago
- Business
- Business Upturn
Viatris Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Viatris Inc. ('Viatris' or the 'Company') (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team: Viatris Lawsuit Submission Form VTRS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Defendants' statements misrepresented the FDA's issuance of a warning letter and its impact on Viatris' operations. Defendants routinely referred to the impact of the warning letter as a mere 'minor headwind' for the Company. On February 27, 2025, Viatris announced its financial results for the fourth quarter and full fiscal year 2024 and provided disappointing fiscal 2025 guidance. The Company attributed below-expectation guidance on 'the expected financial impact from Indore facility warning letter and import alert.' Following this news, the price of Viatris' common stock declined dramatically. From a closing market price of $11.24 per share on February 26, 2025, Viatris' stock price fell to $9.53 per share on February 27, 2025, a decline of about 15.21% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Viatris during the relevant time frame, you have until June 3, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004 [email protected] Tel: (212) 363-7500Fax: (212) 363-7171
